Kalohexis doses first patients in 710GO Phase I trial for obesity

Kalohexis Doses First Patients in Phase I Obesity Trial for 710GO

Kalohexis has initiated a Phase I first-in-human clinical trial for 710GO, an oral dual melanocortin-3 receptor/melanocortin-4 receptor (MC3R/MC4R) agonist, for general obesity treatment. The randomized, double-blind, placebo-controlled study, conducted in Australia, will recruit approximately 100 healthy overweight or obese volunteers. It aims to assess 710GO's pharmacodynamics, pharmacokinetics, preliminary efficacy, safety, and tolerability. Preclinical data showed consistent weight loss with minimal side effects, suggesting its potential as a standalone or combination therapy.

• The Phase I trial is a randomized, double-blind, placebo-controlled study with single-ascending dose, 28-day multiple-ascending dose, and food effect components. Its primary objectives are to evaluate 710GO’s pharmacodynamics, pharmacokinetics, preliminary efficacy, safety, and tolerability in approximately 100 healthy overweight or obese volunteers in Australia.
• 710GO is an oral dual MC3R/MC4R agonist designed to activate the melanocortin system, the body's natural regulator of metabolic homeostasis, to establish a new metabolic set point. Preclinical studies in non-human primates demonstrated 11.7% body weight reduction over 13 weeks, primarily from decreased fat mass, without significant gastrointestinal or cardiovascular adverse events.
• Kalohexis believes 710GO has the potential to overcome limitations of current standard-of-care treatments for general obesity. Its unique preclinical profile, showing minimal loss of lean body mass, limited GI issues, and less rapid weight regain compared to GLP-1 receptor agonists, positions it as a differentiated, convenient oral therapy, potentially for standalone use or in combination with other anti-obesity drugs.

Addressing Unmet Needs in General Obesity Management

Current obesity treatment approaches face significant limitations across therapeutic modalities, with adherence rates below 50% for long-term drug interventions and insufficient efficacy for conventional diet and exercise programs. These challenges highlight the complex nature of obesity management and the need for more effective therapeutic strategies.

• Limited treatment efficacy and high relapse rates - Lifestyle modifications as first-line treatment carry high relapse risk, while physical training and drug therapy approaches often demonstrate unsatisfactory efficacy and prognosis in long-term management

• Poor patient adherence across interventions - Adherence to obesity treatments remains consistently low, with obese patients maintaining recommended drug measures at medium- and long-term intervals at less than 50% rates

• Restricted scope of surgical interventions - Bariatric surgery application is limited to morbid obesity cases only, preventing large-scale utilization for the broader obese population despite its proven effectiveness

• Insufficient pharmacological options - Currently available pharmacological obesity treatments are limited in number and scope, with most targeting single pathways despite obesity's multi-system complexity

• Complex mechanistic requirements - Single pharmacological agents are unlikely to provide striking obesity treatment effects since effective interventions must address multiple systems controlling food intake and energy expenditure simultaneously

• Undefined molecular targets - Binding targets for many natural small molecules including alkaloids and polyphenols remain undefined, limiting mechanistic studies and preventing further therapeutic application development

• Resource-intensive delivery methods - In-person sessions for multicomponent lifestyle interventions prove time-consuming and costly, while digital therapeutic alternatives have shown mixed results with significant efficacy only in highly adherent participants

• Safety and tolerability concerns - Current obesity treatments remain insufficient regarding efficacy, tolerability, and safety profiles, with lifestyle modification, pharmacotherapy, and bariatric surgery all carrying specific limitations in these domains

Unlocking the Melanocortin System for Durable Weight Loss

The obesity therapeutic landscape is rapidly evolving with several promising multi-receptor agonist approaches demonstrating unprecedented efficacy. Dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists, exemplified by tirzepatide, have shown superior weight reduction compared to GLP-1 monotherapy, with clinical trials demonstrating 10-20% body weight reduction and significant cardiovascular risk reduction. Triple receptor agonists targeting GLP-1/GIPR/glucagon receptors represent the next frontier, with retatrutide exhibiting remarkable efficacy in patients with diabetes, obesity, and chronic kidney disease. This investigational agent demonstrates weight loss up to 24.2% with potential renoprotective effects, though it displays a distinctive dose-response pattern where lower doses may provide superior glycemic control.

Beyond incretin-based therapies, amylin analogs are emerging as compelling targets for durable weight management. Cagrilintide, a long-acting amylin analog, has produced substantial weight reduction in clinical trials, with combination therapy alongside GLP-1 receptor agonists achieving synergistic effects exceeding 15% weight loss. The amylin pathway offers unique advantages through delayed gastric emptying, glucagon suppression, and central nervous system-mediated satiety enhancement. Additionally, FGF21 analogs represent promising pharmacologic agents that may simultaneously reduce liver fat and alcohol consumption, particularly relevant for metabolic dysfunction-associated conditions.

A critical emerging focus involves muscle preservation strategies during weight loss, as research has identified over 600 myokines associated with muscle contraction that may preserve both muscle mass and function. This represents a paradigm shift toward treatments that selectively reduce fat mass while minimizing lean mass loss or potentially promoting muscle gain. Concurrently, personalized medicine approaches are gaining traction, with treatment algorithms integrating individual comorbidities, phenotypes, genetic markers, and early response predictors to optimize therapeutic outcomes in this highly variable patient population.

Oral MC Agonist: Expanding the Melanocortin Pathway in General Obesity

The initiation of a Phase I clinical trial for Kalohexis's 710GO, an oral dual melanocortin-3 receptor/melanocortin-4 receptor (MC3R/MC4R) agonist, marks a pivotal moment for the melanocortin pathway in obesity therapeutics. While the pathway is well-established for its critical role in controlling food intake and body adiposity, and MC4R agonists like setmelanotide have achieved success in treating rare monogenic forms of obesity, 710GO aims to address the much broader challenge of general obesity. This represents a strategic attempt to expand the therapeutic reach of melanocortin modulation beyond specific genetic deficiencies.

A key differentiator for 710GO is its oral administration, offering a significant convenience advantage over many existing injectable obesity treatments, including other melanocortin agonists and the widely used GLP-1 receptor agonists. Furthermore, preclinical data suggesting consistent weight loss with minimal side effects are encouraging, especially given the historical challenges with the class. However, the path forward is not without considerable hurdles.

• Translational Efficacy: Demonstrating robust efficacy in the heterogeneous population of general obesity, where the underlying mechanisms are complex, will be critical. Previous attempts with MC4R agonists in broader populations have yielded mixed results, highlighting the difficulty in translating success from monogenic forms.

• Safety Profile: The melanocortin pathway is known to influence cardiovascular function, with some MC4R agonists previously linked to increases in blood pressure and heart rate. Other reported adverse events include sexual arousal disturbances and skin reactions. Kalohexis must meticulously monitor these potential class-specific side effects to ensure a favorable safety profile.

• Competitive Landscape: The general obesity market is highly competitive, with powerful GLP-1 receptor agonists already demonstrating substantial weight loss. 710GO will need to present a compelling balance of efficacy, safety, and patient convenience to differentiate itself and secure a meaningful position.

The Phase I trial's focus on pharmacokinetics, pharmacodynamics, and preliminary efficacy will provide crucial early insights into 710GO's potential. If Kalohexis can successfully navigate these challenges and deliver on its preclinical promise, an oral dual MC3R/MC4R agonist could offer a valuable new therapeutic option, either as a standalone treatment or in combination, reshaping the future of obesity pharmacotherapy.